EGFR and neoplasm: The patients with EGFR mutations had a longer median OS than the patients without EGFR mutations, but the difference was not statistically significant (716 vs 193 days, P=0.070, in tumour samples; 387 vs 228 days, P=0.489, in serum samples; Figure 1B).